v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
REVENUES:    
Product revenue $ 10,164,036 $ 3,492,881
License and other revenue 35,708 35,708
Total Revenues 10,199,744 3,528,589
OPERATING EXPENSES    
Cost of product revenue (exclusive of amortization expense shown below) 16,829,226 9,405,179
Research and development 1,528,738 870,635
Plasma center operating expenses 500,644 654,486
Amortization of intangible assets 178,838 211,235
Selling, general and administrative 7,932,084 5,595,470
TOTAL OPERATING EXPENSES 26,969,530 16,737,005
LOSS FROM OPERATIONS (16,769,786) (13,208,416)
OTHER INCOME (EXPENSE):    
Interest and other income 248,068 127,399
Interest expense (2,717,091) (1,540,507)
Loss on extinguishment of debt 0 (9,962,495)
Gain on transfer of plasma center assets 0 11,527,421
Other expense (6,421) (11,357)
Other (expense) income, net (2,475,444) 140,461
NET LOSS $ (19,245,230) $ (13,067,955)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.26) $ (0.28)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted 73,781,507 46,353,068

Source